{"success":true,"data":{"pressRelease":{"id":"88479","rtpr_id":"nPn5LX6D1a","ticker":"3696","exchange":"HKEX","all_tickers":["3696"],"title":"Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development","author":"PR Newswire","published_at":"2026-07-15T00:00:02.444Z","article_body":"Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development\n\nPR Newswire\n\nCAMBRIDGE, Mass. and TAIPEI, July 14, 2026\n\nCombines Insilico's Pharma.AI platform with Bora's global development,\nmanufacturing, quality, and commercialization capabilities to explore a\nnext-generation drug innovation model\n\nCAMBRIDGE, Mass. and TAIPEI, July 14, 2026 /PRNewswire/ -- Insilico Medicine\n(\"Insilico\"; HKEX: 3696), a clinical-stage generative artificial intelligence\n(AI)-driven drug discovery company, today announced a multi-target strategic\nalliance with Bora Pharmaceuticals Co., Ltd. (\"Bora\"; TWSE: 6472; OTCQX:\nBORAY), a global leader in pharmaceutical manufacturing.\n\nThe proposed alliance will be governed by definitive agreements to be\ndiscussed and executed by Insilico and Bora and is designed to combine\nInsilico's proprietary Pharma.AI platform, spanning target discovery,\ngenerative chemistry, and molecule optimization, with Bora's global\ndevelopment, manufacturing, quality, and commercialization capabilities.  By\nlinking AI-enabled discovery with automation-driven development,\nmanufacturing, and quality execution, Insilico and Bora aim to pioneer a\nnext-generation drug innovation model that connects novel molecule design with\nthe capabilities required to develop, manufacture, and deliver medicines to\npatients with unmet medical needs.\n\nThe alliance lays the foundation for a broad, multi-target collaboration\nframework, subject to the parties' further discussion and execution of\ndefinitive agreements. If fully implemented, the potential value of the\nproposed collaboration could exceed US$2.5 billion. Insilico expects to\nsupport Bora in strengthening AI capabilities across its global workforce and\nenhancing AI literacy across the organization. The partnership is also\nexpected to apply Insilico's AI capabilities to improve efficiency across\nmanufacturing, supply chain, distribution, and corporate operations. As the\ncollaboration progresses, Bora and Insilico expect to further refine its\nscope, scale, and operating framework.\n\nAs part of the alliance, Insilico aims to accelerate Bora's transition toward\nmore AI-driven and automation-driven drug discovery and development\ncapabilities by providing comprehensive research and development strategies\nand end-to-end AI solutions across global discovery and development workflows.\nOver time, the alliance will further explore opportunities to apply AI and\nautomation-driven approaches across development planning, process\noptimization, pharmaceutical development, manufacturing readiness, and quality\nsystems.\n\nThe proposed alliance reflects a shared vision that the next generation of\nbiopharmaceutical innovation will be increasingly AI-native, data-rich, and\nautomation-driven. In this new model, value will be created not only through\nthe discovery and design of novel molecules, but also through smarter, more\nefficient translation of those molecules into high-quality development\nprograms and, ultimately, medicines for patients. Insilico brings an AI-native\ndiscovery engine with demonstrated productivity across multiple therapeutic\nareas, while Bora brings deep experience in drug development, global\nmanufacturing, quality systems, supply chain execution, and commercialization.\n\n\"Insilico Medicine has established itself as one of the world's leading AI\ndrug discovery companies by demonstrating that generative AI can identify\nnovel targets, design novel molecules, and advance drug candidates into\nclinical development,\" said Bobby Sheng, founder, Chairman of Bora Group and\nCEO of Bora Pharmaceuticals. \"This strategic alliance marks an important step\nin Bora's evolution from a leading pharmaceutical development and\nmanufacturing partner into a broader drug innovation ecosystem. By\ncombining Insilico's AI-native capabilities with Bora's global expertise in\nformulation, CMC, regulatory development, scale-up, quality, commercial\nmanufacturing, supply chain, and commercialization, we have an opportunity to\ncreate a truly integrated pathway from discovery to commercialization.\n\n\"AI is already transforming drug discovery, but its full potential will only\nbe realized when that transformation extends across the entire development and\nmanufacturing value chain. This is not simply about adding AI to existing\nprocesses; it is about reimagining how pharmaceutical products are developed,\nmanufactured, and brought to patients. Together, we aim to build a scalable\nand repeatable model that can advance promising drug candidates more\nefficiently, positioning Bora at the forefront of AI-enabled pharmaceutical\ndevelopment and manufacturing, and establish a long-term growth platform\nthrough the development and commercialization of high-value proprietary\nassets.\"\n\n\"We are thrilled to partner with Bora, a visionary leader with world-class\ndevelopment and manufacturing capabilities and a strong commitment to\nAI-driven innovation,\" said Dr. Alex Zhavoronkov, founder, co-CEO, and CBO of\nInsilico Medicine. \"Building on our collaborations with Takeda and SK\nBiopharmaceuticals in Asia-Pacific, this alliance with Bora further\ndemonstrates Insilico's commitment to partnering with leading\nbiopharmaceutical innovators across the region. Insilico has built a powerful\nAI-native engine for target discovery, generative chemistry, and molecule\noptimization. Together with Bora, we aim to connect that discovery engine with\nthe capabilities required to advance high-quality drug candidates through\ndevelopment, manufacturing, and potential commercialization, while also\nsupporting Bora's broader AI transformation. This alliance represents an\nimportant step toward demonstrating how AI-discovered medicines can be\ndeveloped faster, more efficiently, and with greater scalability.\"\n\nAs an AI-native biotechnology company, Insilico is redefining the efficiency\nof preclinical drug development through its advanced AI and automation\nplatform. While traditional early-stage drug discovery typically takes 2.5 to\n4 years, Insilico has consistently reached preclinical candidate (\"PCC\")\nnomination in an average of just 12 to 18 months. Since 2021, the company has\nnominated 31 PCCs, 13 of which have received IND approval or clearance – a\ntrack record of speed and productivity that this alliance aims to pair with\nBora's development and manufacturing scale.\n\nWhile expanding the practical applications of its technology in drug discovery\nand life science research, Insilico is also continuously enhancing the\nperformance of its AI platform. Drawing on extensive experience and datasets\nfrom its training platform, the company has distilled thousands of benchmarks\nand integrated them into MMAI Gym. Serving as both a \"trainer and benchmark\"\nfor scientific AI, MMAI Gym enables organizations to train models for\ndomain-specific reasoning while rigorously evaluating their performance on\nreal-world tasks, advancing the path toward pharma superintelligence. To date,\nHuman Longevity and Liquid AI have collaborated with Insilico, joining as\npartners of MMAI Gym.\n\nAbout Insilico Medicine\n\nInsilico Medicine is a pioneering global biotechnology company dedicated to\nintegrating artificial intelligence and automation technologies to accelerate\ndrug discovery, drive innovation in the life sciences, and extend healthy\nlongevity to people on the planet. The company was listed on the Main Board of\nthe Hong Kong Stock Exchange on December 30, 2025, under the stock code\n03696.HK.\n\nBy integrating AI and automation technologies and deep in-house drug discovery\ncapabilities, Insilico is delivering innovative drug solutions for unmet needs\nincluding fibrosis, oncology, immunology, pain, and obesity and metabolic\ndisorders. Additionally, Insilico extends the reach of Pharma.AI across\ndiverse industries, such as advanced materials, agriculture, nutritional\nproducts and veterinary medicine. For more information, please visit\n(http://www.insilico.com/) www.insilico.com (http://www.insilico.com/)\n\nAbout Bora Pharmaceuticals\n\nFounded in 2007, Bora Pharmaceuticals Co., Ltd. (\"Bora\" or \"the Company\",\n6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a\nvision and goal of \"Contributing to Better Health All Over the World\".\nOperating under a \"Dual Engine\" model that integrates CDMO and commercial\nexpertise, we empower pharmaceutical and biotech partners to optimize product\ndevelopment, accelerate launches, and scale supply to meet global patient\nneeds. At the same time, we actively broaden R&D and sales infrastructure,\nfocusing on niche and rare disease markets to improve patients' quality of\nlife. For more information, please visit  (http://www.bora-corp.com/)\nwww.bora-corp.com (http://www.bora-corp.com/)\n\nForward-Looking Statements:\n\nThis press release contains forward-looking statements relating to the likely\nfuture developments in the business of the Company and its subsidiaries, such\nas expected future events, business prospects or financial performance. The\nwords \"expect\", \"anticipate\", \"continue\", \"estimate\", \"objective\", \"ongoing\",\n\"may\", \"will\", \"project\", \"should\", \"believe\", \"plans\", \"intends\", \"visions\",\n\"schedule\" and similar expressions are intended to identify such\nforward-looking statements. These statements are based on assumptions and\nanalyses made by the Company at the time of this press release in light of its\nexperience and its perception of historical trends, current conditions and\nexpected future developments, as well as other factors that the Company\ncurrently believes are appropriate under the circumstances. However, whether\nactual results and developments will meet the current expectations and\npredictions of the Company is uncertain.  Actual results, performance and\nfinancial condition may differ materially from the Company's expectations.\n\nAll of the forward-looking statements made in this press release are qualified\nby these statements. Consequently, the inclusion of forward-looking statements\nin this press release should not be regarded as representations by the Board\nor the Company that the plans and objectives will be achieved, and investors\nshould not place undue reliance on such statements.\n\nThe Company, its Board, the employees and the agents of the Company assume (a)\nno obligation to correct or update the forward-looking statements contained in\nthis press release; and (b) no liability for any losses in the event that any\nof the forward-looking statements do not materialise or turn out to be\nincorrect.\n\nView original\ncontent:https://www.prnewswire.com/news-releases/insilico-medicine-and-bora-pharmaceuticals-announce-strategic-alliance-for-ai-driven-drug-discovery-and-development-302824911.html\n(https://www.prnewswire.com/news-releases/insilico-medicine-and-bora-pharmaceuticals-announce-strategic-alliance-for-ai-driven-drug-discovery-and-development-302824911.html)\n\nSOURCE Insilico Medicine\n\n\n\nJoy Hu, joy@insilico.ai, 13818050383\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn5LX6D1a","title":"Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development","author":"PR Newswire","ticker":"3696","created":"2026-07-15T00:00:02.444Z","tickers":["3696"],"exchange":"HKEX","article_body":"Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development\n\nPR Newswire\n\nCAMBRIDGE, Mass. and TAIPEI, July 14, 2026\n\nCombines Insilico's Pharma.AI platform with Bora's global development,\nmanufacturing, quality, and commercialization capabilities to explore a\nnext-generation drug innovation model\n\nCAMBRIDGE, Mass. and TAIPEI, July 14, 2026 /PRNewswire/ -- Insilico Medicine\n(\"Insilico\"; HKEX: 3696), a clinical-stage generative artificial intelligence\n(AI)-driven drug discovery company, today announced a multi-target strategic\nalliance with Bora Pharmaceuticals Co., Ltd. (\"Bora\"; TWSE: 6472; OTCQX:\nBORAY), a global leader in pharmaceutical manufacturing.\n\nThe proposed alliance will be governed by definitive agreements to be\ndiscussed and executed by Insilico and Bora and is designed to combine\nInsilico's proprietary Pharma.AI platform, spanning target discovery,\ngenerative chemistry, and molecule optimization, with Bora's global\ndevelopment, manufacturing, quality, and commercialization capabilities.  By\nlinking AI-enabled discovery with automation-driven development,\nmanufacturing, and quality execution, Insilico and Bora aim to pioneer a\nnext-generation drug innovation model that connects novel molecule design with\nthe capabilities required to develop, manufacture, and deliver medicines to\npatients with unmet medical needs.\n\nThe alliance lays the foundation for a broad, multi-target collaboration\nframework, subject to the parties' further discussion and execution of\ndefinitive agreements. If fully implemented, the potential value of the\nproposed collaboration could exceed US$2.5 billion. Insilico expects to\nsupport Bora in strengthening AI capabilities across its global workforce and\nenhancing AI literacy across the organization. The partnership is also\nexpected to apply Insilico's AI capabilities to improve efficiency across\nmanufacturing, supply chain, distribution, and corporate operations. As the\ncollaboration progresses, Bora and Insilico expect to further refine its\nscope, scale, and operating framework.\n\nAs part of the alliance, Insilico aims to accelerate Bora's transition toward\nmore AI-driven and automation-driven drug discovery and development\ncapabilities by providing comprehensive research and development strategies\nand end-to-end AI solutions across global discovery and development workflows.\nOver time, the alliance will further explore opportunities to apply AI and\nautomation-driven approaches across development planning, process\noptimization, pharmaceutical development, manufacturing readiness, and quality\nsystems.\n\nThe proposed alliance reflects a shared vision that the next generation of\nbiopharmaceutical innovation will be increasingly AI-native, data-rich, and\nautomation-driven. In this new model, value will be created not only through\nthe discovery and design of novel molecules, but also through smarter, more\nefficient translation of those molecules into high-quality development\nprograms and, ultimately, medicines for patients. Insilico brings an AI-native\ndiscovery engine with demonstrated productivity across multiple therapeutic\nareas, while Bora brings deep experience in drug development, global\nmanufacturing, quality systems, supply chain execution, and commercialization.\n\n\"Insilico Medicine has established itself as one of the world's leading AI\ndrug discovery companies by demonstrating that generative AI can identify\nnovel targets, design novel molecules, and advance drug candidates into\nclinical development,\" said Bobby Sheng, founder, Chairman of Bora Group and\nCEO of Bora Pharmaceuticals. \"This strategic alliance marks an important step\nin Bora's evolution from a leading pharmaceutical development and\nmanufacturing partner into a broader drug innovation ecosystem. By\ncombining Insilico's AI-native capabilities with Bora's global expertise in\nformulation, CMC, regulatory development, scale-up, quality, commercial\nmanufacturing, supply chain, and commercialization, we have an opportunity to\ncreate a truly integrated pathway from discovery to commercialization.\n\n\"AI is already transforming drug discovery, but its full potential will only\nbe realized when that transformation extends across the entire development and\nmanufacturing value chain. This is not simply about adding AI to existing\nprocesses; it is about reimagining how pharmaceutical products are developed,\nmanufactured, and brought to patients. Together, we aim to build a scalable\nand repeatable model that can advance promising drug candidates more\nefficiently, positioning Bora at the forefront of AI-enabled pharmaceutical\ndevelopment and manufacturing, and establish a long-term growth platform\nthrough the development and commercialization of high-value proprietary\nassets.\"\n\n\"We are thrilled to partner with Bora, a visionary leader with world-class\ndevelopment and manufacturing capabilities and a strong commitment to\nAI-driven innovation,\" said Dr. Alex Zhavoronkov, founder, co-CEO, and CBO of\nInsilico Medicine. \"Building on our collaborations with Takeda and SK\nBiopharmaceuticals in Asia-Pacific, this alliance with Bora further\ndemonstrates Insilico's commitment to partnering with leading\nbiopharmaceutical innovators across the region. Insilico has built a powerful\nAI-native engine for target discovery, generative chemistry, and molecule\noptimization. Together with Bora, we aim to connect that discovery engine with\nthe capabilities required to advance high-quality drug candidates through\ndevelopment, manufacturing, and potential commercialization, while also\nsupporting Bora's broader AI transformation. This alliance represents an\nimportant step toward demonstrating how AI-discovered medicines can be\ndeveloped faster, more efficiently, and with greater scalability.\"\n\nAs an AI-native biotechnology company, Insilico is redefining the efficiency\nof preclinical drug development through its advanced AI and automation\nplatform. While traditional early-stage drug discovery typically takes 2.5 to\n4 years, Insilico has consistently reached preclinical candidate (\"PCC\")\nnomination in an average of just 12 to 18 months. Since 2021, the company has\nnominated 31 PCCs, 13 of which have received IND approval or clearance – a\ntrack record of speed and productivity that this alliance aims to pair with\nBora's development and manufacturing scale.\n\nWhile expanding the practical applications of its technology in drug discovery\nand life science research, Insilico is also continuously enhancing the\nperformance of its AI platform. Drawing on extensive experience and datasets\nfrom its training platform, the company has distilled thousands of benchmarks\nand integrated them into MMAI Gym. Serving as both a \"trainer and benchmark\"\nfor scientific AI, MMAI Gym enables organizations to train models for\ndomain-specific reasoning while rigorously evaluating their performance on\nreal-world tasks, advancing the path toward pharma superintelligence. To date,\nHuman Longevity and Liquid AI have collaborated with Insilico, joining as\npartners of MMAI Gym.\n\nAbout Insilico Medicine\n\nInsilico Medicine is a pioneering global biotechnology company dedicated to\nintegrating artificial intelligence and automation technologies to accelerate\ndrug discovery, drive innovation in the life sciences, and extend healthy\nlongevity to people on the planet. The company was listed on the Main Board of\nthe Hong Kong Stock Exchange on December 30, 2025, under the stock code\n03696.HK.\n\nBy integrating AI and automation technologies and deep in-house drug discovery\ncapabilities, Insilico is delivering innovative drug solutions for unmet needs\nincluding fibrosis, oncology, immunology, pain, and obesity and metabolic\ndisorders. Additionally, Insilico extends the reach of Pharma.AI across\ndiverse industries, such as advanced materials, agriculture, nutritional\nproducts and veterinary medicine. For more information, please visit\n(http://www.insilico.com/) www.insilico.com (http://www.insilico.com/)\n\nAbout Bora Pharmaceuticals\n\nFounded in 2007, Bora Pharmaceuticals Co., Ltd. (\"Bora\" or \"the Company\",\n6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a\nvision and goal of \"Contributing to Better Health All Over the World\".\nOperating under a \"Dual Engine\" model that integrates CDMO and commercial\nexpertise, we empower pharmaceutical and biotech partners to optimize product\ndevelopment, accelerate launches, and scale supply to meet global patient\nneeds. At the same time, we actively broaden R&D and sales infrastructure,\nfocusing on niche and rare disease markets to improve patients' quality of\nlife. For more information, please visit  (http://www.bora-corp.com/)\nwww.bora-corp.com (http://www.bora-corp.com/)\n\nForward-Looking Statements:\n\nThis press release contains forward-looking statements relating to the likely\nfuture developments in the business of the Company and its subsidiaries, such\nas expected future events, business prospects or financial performance. The\nwords \"expect\", \"anticipate\", \"continue\", \"estimate\", \"objective\", \"ongoing\",\n\"may\", \"will\", \"project\", \"should\", \"believe\", \"plans\", \"intends\", \"visions\",\n\"schedule\" and similar expressions are intended to identify such\nforward-looking statements. These statements are based on assumptions and\nanalyses made by the Company at the time of this press release in light of its\nexperience and its perception of historical trends, current conditions and\nexpected future developments, as well as other factors that the Company\ncurrently believes are appropriate under the circumstances. However, whether\nactual results and developments will meet the current expectations and\npredictions of the Company is uncertain.  Actual results, performance and\nfinancial condition may differ materially from the Company's expectations.\n\nAll of the forward-looking statements made in this press release are qualified\nby these statements. Consequently, the inclusion of forward-looking statements\nin this press release should not be regarded as representations by the Board\nor the Company that the plans and objectives will be achieved, and investors\nshould not place undue reliance on such statements.\n\nThe Company, its Board, the employees and the agents of the Company assume (a)\nno obligation to correct or update the forward-looking statements contained in\nthis press release; and (b) no liability for any losses in the event that any\nof the forward-looking statements do not materialise or turn out to be\nincorrect.\n\nView original\ncontent:https://www.prnewswire.com/news-releases/insilico-medicine-and-bora-pharmaceuticals-announce-strategic-alliance-for-ai-driven-drug-discovery-and-development-302824911.html\n(https://www.prnewswire.com/news-releases/insilico-medicine-and-bora-pharmaceuticals-announce-strategic-alliance-for-ai-driven-drug-discovery-and-development-302824911.html)\n\nSOURCE Insilico Medicine\n\n\n\nJoy Hu, joy@insilico.ai, 13818050383\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-07-15T00:00:02.49998718Z","server_sent_at_ms":1784073602499},"received_at":"2026-07-15T00:00:02.551Z","source_url":"https://www.prnewswire.com/news-releases/insilico-medicine-and-bora-pharmaceuticals-announce-strategic-alliance-for-ai-driven-drug-discovery-and-development-302824911.html"},"analysis":{"id":"77533","press_release_id":"88479","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["definitive agreements not yet signed","deal value is conditional on full implementation"],"eventType":"partnership","narrative":"Insilico Medicine announced a strategic alliance with Bora Pharmaceuticals to combine its Pharma.AI platform with Bora's global development and manufacturing capabilities.\n\nThe proposed collaboration aims to pioneer a next-generation drug innovation model with a potential value exceeding US$2.5 billion, pending the execution of definitive agreements.\n\nInsilico's CEO highlighted the partnership as a step toward scalable, efficient development of AI-discovered medicines, leveraging the company's track record of 31 preclinical candidate nominations.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Insilico links AI discovery with Bora's manufacturing in a strategic alliance potentially worth over $2.5B."},"keyFigures":{"dealValueUsd":"US$2.5 billion","customDimensions":{"ind_approvals":13,"pcc_nominated":31,"avg_time_to_pcc_months":"12 to 18"}},"quotedText":"We are thrilled to partner with Bora, a visionary leader with world-class development and manufacturing capabilities and a strong commitment to AI-driven innovation","namedEntities":{"people":[{"name":"Dr. Alex Zhavoronkov","role":"founder, co-CEO, and CBO of Insilico Medicine"},{"name":"Bobby Sheng","role":"founder, Chairman of Bora Group and CEO of Bora Pharmaceuticals"}],"products":["Pharma.AI","MMAI Gym"],"companies":[{"name":"Bora Pharmaceuticals Co., Ltd.","ticker":"6472","relationship":"partner"},{"name":"Takeda","relationship":"partner"},{"name":"SK Biopharmaceuticals","relationship":"partner"},{"name":"Human Longevity","relationship":"partner"},{"name":"Liquid AI","relationship":"partner"}],"dollarAmounts":[{"amount":"US$2.5 billion","context":"potential value of the proposed collaboration"}]},"materialImpact":{"score":3,"reasoning":"High headline potential value of $2.5 billion combining AI discovery with global manufacturing capabilities. However, the collaboration is currently non-binding and subject to definitive agreements not yet signed, which introduces execution risk."},"tickerRelevance":{"others":[{"ticker":"6472","relevance":"partner"}],"primary":"3696"},"globalImportance":35,"audienceRelevance":40,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-mid-cap","eventGravity":"high-potential-value-partnership","sectorWeight":"biotech-ai"}},"event_type":"partnership","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Insilico Medicine announced a strategic alliance with Bora Pharmaceuticals to combine its Pharma.AI platform with Bora's global development and manufacturing capabilities.\n\nThe proposed collaboration aims to pioneer a next-generation drug innovation model with a potential value exceeding US$2.5 billion, pending the execution of definitive agreements.\n\nInsilico's CEO highlighted the partnership as a step toward scalable, efficient development of AI-discovered medicines, leveraging the company's track record of 31 preclinical candidate nominations.","key_figures":{"dealValueUsd":"US$2.5 billion","customDimensions":{"ind_approvals":13,"pcc_nominated":31,"avg_time_to_pcc_months":"12 to 18"}},"named_entities":{"people":[{"name":"Dr. Alex Zhavoronkov","role":"founder, co-CEO, and CBO of Insilico Medicine"},{"name":"Bobby Sheng","role":"founder, Chairman of Bora Group and CEO of Bora Pharmaceuticals"}],"products":["Pharma.AI","MMAI Gym"],"companies":[{"name":"Bora Pharmaceuticals Co., Ltd.","ticker":"6472","relationship":"partner"},{"name":"Takeda","relationship":"partner"},{"name":"SK Biopharmaceuticals","relationship":"partner"},{"name":"Human Longevity","relationship":"partner"},{"name":"Liquid AI","relationship":"partner"}],"dollarAmounts":[{"amount":"US$2.5 billion","context":"potential value of the proposed collaboration"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-15T00:04:15.628Z","global_importance":35,"audience_relevance":40,"importance_components":{"tickerTier":"small-mid-cap","eventGravity":"high-potential-value-partnership","sectorWeight":"biotech-ai"}},"durationMs":253046,"modelName":"glm-4.7"}}